Skip to content
TRENDING:
Charlie Kirk
Advertisement

FILE - This Aug. 2, 2018, file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. Investors are driving shares of drug developer BioMarin down by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients. The FDA's rejection late Tuesday, Aug. 18, 2020, means BioMarin will have to complete an ongoing late-stage patient study. (AP Photo/Jacquelyn Martin, File)

FILE - This Aug. 2, 2018, file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. Investors are driving shares of drug developer BioMarin down by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients. The FDA's rejection late Tuesday, Aug. 18, 2020, means BioMarin will have to complete an ongoing late-stage patient study. (AP Photo/Jacquelyn Martin, File)

Featured Photo Galleries

01-Army parade.png

Military parade celebrates Army’s 250th

Cheers and chants rang out Saturday from a crowd of thousands as soldiers manned modern and historic tanks and aircraft for the Army’s 250th anniversary celebration in the District.

20250330 Sabatini-Caps-Sabres 001.jpg

Ovi scores goal 890, Caps lose to Sabres 8-5

Alexander Ovechkin scored goal number 890, but the Washington Capitals fell short, losing to the visiting Buffalo Sabres Sunday afternoon 8-5 at Capital One Arena in Washington D.C., March 30, 2025 (Photos for the Washington Times.)